Acquisition of BioServe Biotechnologies India Pvt. Ltd.
26 April 2018
REPROCELL announces that it has acquired all the shares of BioServe Biotechnologies India Pvt. Ltd., (Hyderabad, India hereinafter referred to as “BioServe India”) from Cancer Genetics Inc. (USA). Bioserve India now becomes a subsidiary of ...
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
18 April 2018
REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP. The week-long mission (9-13 April 2018) included meetings with senior busin...
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
REPROCELL Europe Ltd was pleased to receive a visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017. CEO Dr David Bunton welcomed Derek Mackay, and he and some REPROCELL ...
REPROCELL’s David Bunton addresses the Scottish Parliament
21 March 2018
On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance. He was also joined by: • Dr Diane Ha...
Patient-derived tumor organoids recapitulate clinical treatments
14 March 2018
The pharmaceutical industry suffers from very high rates of clinical failure, because preclinical predictions of efficacy often fail to realize a clinical benefit. In part, this can be attributed to an over-reliance on animal models of effi...
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
24 January 2018
The SMi Group’s conference on 3D Cell Culture will be held on 21-22 February 2018.The venue is the Copthorne Tara Hotel in Kensington, London, UK. Find out more at www.3d-CellCulture.com REPROCELL Europe’s CSO Professor Stefan Przyborski wi...
Formation of human tissue to improve drug testing and reduce animal research
19 January 2018
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, was in Durham University (UK) News. Developed at the university by Professor Stefan Prsyborski, Alvetex was first commercialised by the spin-out company Re...
REPROCELL Launches New Global Website
15 January 2018
Regional companies and brands are integrated into one comprehensive English website demonstrating synergies of REPROCELL’s unique portfolio. Location: REPROCELL Inc. (Yokoyama, Japan) Business Unit: REPROCELL Inc. (Yokoyama, Japan) REPROCEL...
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
29 November 2017
New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products YOKOHAMA, JAPAN & SALT LAKE CITY, UTAH – November 29th, 2017 – REPROCELL, Inc. announced a collaborative research agreement with Q Therapeutics, Inc. that co...
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
08 November 2017
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exch...